• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20042 / SuperGen Provides Additional Analysis of Response Data from Phase III Study...

SuperGen Provides Additional Analysis of Response Data from Phase III Study of Dacogen in MDS

24 May 2004/in 2004, News

SuperGen Provides Additional Analysis of Response Data from Phase III Study of Dacogen in MDS

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2004-05-24 14:29:312016-11-28 14:29:53SuperGen Provides Additional Analysis of Response Data from Phase III Study of Dacogen in MDS

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen Announces Study of Novel Regimen Using Nipent® for Hematopoietic Stem Cell Transplantation Published in Journal of Bone Marrow Transplantation Link to: SuperGen Announces Study of Novel Regimen Using Nipent® for Hematopoietic Stem Cell Transplantation Published in Journal of Bone Marrow Transplantation SuperGen Announces Study of Novel Regimen Using Nipent® for Hematopoietic Stem... Link to: SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™ Link to: SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™ SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.